Genprex received a deficiency notice from Nasdaq on June 10, 2026, for failing to maintain a minimum bid price of $1.00 per share. The company is ineligible for a standard 180-day compliance period due to a reverse stock split effected on October 21, 2025. Management intends to request a hearing before a Nasdaq Hearings Panel to stay any immediate delisting action. The company is considering a potential reverse stock split as a mechanism to regain compliance with listing requirements.